PNV Share Price Performance
AU$1.19
-1.11 (-48.26%)
54.2% undervalued intrinsic discount
AU$2.60
Fair Value
Price AU$1.19
AnalystHighTarget AU$2.60
AnalystConsensusTarget AU$1.98
AnalystLowTarget AU$1.15
Fair ValueAU$2.60
Share PriceAU$1.19
54.2% undervalued intrinsic discount
PNV Community Narratives
AN
Fair Value AU$2.60 53.5% undervalued intrinsic discount
Aging Populations And Rising Diabetes Will Expand Advanced Wound Care
0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
AN
Fair Value AU$1.98 39.0% undervalued intrinsic discount
NovoSorb MTX Launch And Global Expansion Will Strengthen Future Business Prospects
0users have liked this narrative
2users have commented on this narrative
32users have followed this narrative
AN
Fair Value AU$1.15 5.2% overvalued intrinsic discount
Global Cost Pressures And Regulatory Risks Will Cripple Future Prospects
0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
PNV Community Fair Values
- AU$1.98FV39.0% undervalued intrinsic discount19.77%Revenue growth p.a.0users have liked this narrative2users have commented on this narrative32users have followed this narrative5 days ago author updated this narrative
- AU$1.15FV5.2% overvalued intrinsic discount20.39%Revenue growth p.a.0users have liked this narrative0users have commented on this narrative0users have followed this narrativeNew narrative
- AU$2.60FV53.5% undervalued intrinsic discount20.36%Revenue growth p.a.0users have liked this narrative0users have commented on this narrative0users have followed this narrativeNew narrative
Recent PNV News & Updates
No updates
PolyNovo Limited Key Details
Last Reported Earnings
Dec 31, 2024
Next Reporting Earnings
Aug 25, 2025
- Earnings per share (EPS)
- 0.0085
- Gross Margin
- 86.40%
- Net Profit Margin
- 5.11%
- Debt/Equity Ratio
- 4.5%
PolyNovo Limited Competitors
About PNV
- Founded
- 1998
- Employees
- 282
- CEO
- WebsiteView website
PolyNovo Limited designs, manufactures, and sells biodegradable medical devices in the United States, Australia, New Zealand, and internationally. The company offers NovoSorb Biodegradable Temporising Matrix, a dermal scaffold for the regeneration of the dermis when lost through extensive surgery, trauma, or burn. It is also developing hernia devices for hernia repair and solution for ventral hernia and complex abdominal wall reconstruction; NovoSorb Dermal Beta Cell, a novel intracutaneous ectopic pancreas to treat type 1 diabetes; NovoSorb MTX for single stage grafting in burns, chronic, and surgical wounds; and plastics and reconstructive device products. The company was formerly known as Calzada Limited and changed its name to PolyNovo Limited in November 2014. PolyNovo Limited was incorporated in 1998 and is headquartered in Port Melbourne, Australia.
Australian Market Performance
- 7 Days: -0.4%
- 3 Months: 6.8%
- 1 Year: 13.2%
- Year to Date: 5.2%
Over the last 7 days, the market has remained flat, although notably the Materials sector declined by 4.2%. As for the longer term, the market has risen 8.6% in the past 12 months. Earnings are forecast to grow by 11% annually. Market details ›
This week, we’re diving deeper into the world of agentic AI. We’re zeroing in on the core technologies that make these intelligent agents actually reliably work. We explore what all this could mean for software, start-ups, and most importantly, the opportunities and risks each industry faces by adopting Agentic AI.
Continue reading